Fluconazole tablet dosages for different fungal conditions and duration of treatment
Reading File
Finding Sources
Searching PubMed
fluconazole dosing fungal infections
Reading File
Reading File
Reading File
Reading File
Finding Sources
Reading File
Reading File
I now have comprehensive data from multiple authoritative textbooks. Let me compile the answer.
Fluconazole — Dosages by Fungal Condition
Fluconazole is an orally bioavailable (~90%) bis-triazole with excellent CSF penetration and a half-life of 25–30 hours. Dose range spans 100–800 mg/day depending on indication. Renal dose adjustment is required (CrCl 21–40 mL/min → dose every 48 h; CrCl 10–20 mL/min → every 72 h; post-hemodialysis → extra 100–200 mg dose).
Candidal Infections
| Condition | Dose | Duration |
|---|---|---|
| Vulvovaginal candidiasis (uncomplicated) | 150 mg single oral dose | 1 day |
| Oropharyngeal candidiasis | 100–200 mg/day | 7–14 days |
| Esophageal candidiasis | 200 mg/day (up to 400 mg/day) | 14–21 days |
| Candidemia (non-immunosuppressed, susceptible isolate, step-down) | 800 mg loading dose, then 400 mg/day | Until blood cultures clear + 14 days after last positive culture |
| Deep-seated/invasive candidiasis (continuation/step-down from echinocandin) | 400 mg/day | Per clinical response |
| Candida endocarditis (relapse prevention) | 400 mg/day | Long-term (indefinite) |
| Chronic mucocutaneous candidiasis | 300 mg/week | 2 weeks (acute); monthly for prophylaxis |
| Prophylaxis in immunocompromised (bone marrow transplant) | 400 mg/day | Duration of neutropenia risk |
| Fluconazole-refractory candidiasis (AIDS patients) | Increase dose, or switch to itraconazole suspension 200 mg/day | — |
Note: For candidemia in immunocompromised patients or severely ill patients, echinocandins are preferred first-line; fluconazole is reserved for susceptible isolates as step-down therapy. — Goldman-Cecil Medicine
Cryptococcal Meningitis
| Phase | Dose | Duration |
|---|---|---|
| Induction | Amphotericin B + flucytosine (fluconazole not first-line alone) | ≥2 weeks |
| Consolidation | 400 mg/day (after induction) | 8 weeks |
| Maintenance/suppression (AIDS) | 200 mg/day | Indefinitely (until CD4 >200/mm³ for ≥6 months on ART) |
| Non-AIDS patients (continuation after AMB) | 400 mg/day | Until clinically stable; 12 months total |
Fluconazole is the azole of choice for treatment and secondary prophylaxis of cryptococcal meningitis owing to its excellent CSF penetration. — Katzung's Basic & Clinical Pharmacology, 16th Ed.
Dermatophytoses (off-label use where itraconazole/terbinafine are contraindicated)
| Condition | Dose | Duration |
|---|---|---|
| Tinea corporis, tinea barbae, tinea pedis | 150 mg once weekly | 2–4 weeks |
| Tinea cruris, tinea capitis | 150 mg once weekly | 4–6 weeks |
| Onychomycosis — fingernails (adults) | 150–450 mg once weekly | 3 months |
| Onychomycosis — toenails (adults) | 150–450 mg once weekly | 6 months |
| Onychomycosis (children) | 3–6 mg/kg/week | Fingernails: 6–12 weeks; Toenails: 9–15 weeks |
— Fitzpatrick's Dermatology, Table 188-2
Pityriasis Versicolor (Tinea Versicolor)
| Dose | Duration |
|---|---|
| 300 mg/week | 2 weeks (treatment); once monthly for prophylaxis |
Coccidioidomycosis
| Indication | Dose | Duration |
|---|---|---|
| Meningitis, pulmonary, soft tissue | 400 mg/day | Long-term; often indefinite for meningitis |
Fluconazole is the preferred azole for coccidioidal meningitis. Activity against other dimorphic fungi (histoplasmosis, blastomycosis) is limited — itraconazole is preferred for those. — Katzung; Goldman-Cecil
Other Uses / Prophylaxis
| Use | Dose | Duration |
|---|---|---|
| Prophylaxis — bone marrow transplant | 400 mg/day | Duration of immunosuppression risk |
| Peritoneal dialysis (antifungal prophylaxis) | 200 mg/day | Per clinical protocol |
| Intra-abdominal surgery / severe pancreatitis | 400 mg/day | Short course, per risk period |
Key Practical Points
- Spectrum: Active against C. albicans, C. parapsilosis, C. neoformans, coccidioides; not active against C. krusei (intrinsic resistance), reduced activity against C. glabrata, C. auris; no activity against Aspergillus or mucormycetes.
- Drug interactions: Inhibits CYP2C9 (moderately) and CYP3A4 (weakly); avoid with QT-prolonging agents (cisapride, pimozide, astemizole) due to risk of torsades de pointes.
- Pregnancy: Teratogenic — avoid, especially high-dose long-term use; single 150 mg dose is considered lower risk but should be used cautiously.
- Liver: Minimal hepatic metabolism; safer than ketoconazole/itraconazole in hepatic impairment.
Sources: Katzung's Basic & Clinical Pharmacology 16th Ed. | Goodman & Gilman's Pharmacological Basis of Therapeutics | Goldman-Cecil Medicine | Fitzpatrick's Dermatology | Lippincott Illustrated Reviews: Pharmacology
This is a shared conversation. Sign in to Orris to start your own chat.